Clicky

Rapport Therapeutics, Inc. Common Stock(RAPP)

Description: Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule medicines for patients suffering from central nervous system (CNS) disorders. Its lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorder. The company also develops RAP-199, a TARPy8 targeted molecule with differentiated chemical and pharmacokinetic properties; and nicotinic acetylcholine receptor (nAChR) programs, such as a6 nAChR to treat chronic pain and a9a10 nAChR for the treatment of hearing disorders. Rapport Therapeutics, Inc. was incorporated in 2022 and is headquartered in Boston, Massachusetts.


Keywords: Chemical Biopharmaceutical Pain Disorders Chronic Pain Cell Signaling Bipolar Disorder Cns Disorders Quaternary Ammonium Compounds Acetylcholine Hearing Disorders Ion Channels Nicotinic Agonist

Home Page: www.rapportrx.com

1325 Boylston Street
Boston, MA 02215
United States
Phone: 857 321 8020


Officers

Name Title
Dr. Steven M. Paul M.D. Founder & Independent Chairman
Mr. Abraham N. Ceesay M.B.A. CEO, President, Treasurer & Director
Dr. Troy A. Ignelzi Chief Financial Officer
Ms. Cheryl Gault Chief Operating Officer
Mr. David Bredt M.D., Ph.D. Founder & Chief Scientific Officer
Ms. Karina Chmielewski Chief Information Officer & Head of Operations
Ms. Julie DiCarlo Head of Communications & Investor Relations
Ms. Kathleen A. Wilkinson Chief People Officer
Dr. Bradley S. Galer M.D. Chief Medical Officer
Mr. Swamy Yeleswaram Ph.D. Chief Development Officer

Exchange: NASDAQ

Country: US : United States of America

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 2.2626
Price-to-Sales TTM: 0
IPO Date: 2024-06-07
Fiscal Year End: December
Full Time Employees: 0
Back to stocks